Synthetic Bone Graft

Opus Mg Set is a magnesium-based settable bone void filler for orthopedic procedures.

The injectable bone substitute is now FDA 510(k) cleared for augmenting suture anchor fixation.

The clearance follows existing clearances by the FDA for the use of MagnetOs Granules and MagnetOs Putty in the spine.

The first patient has been treated in a study to investigate OssDsign Catalyst in patients undergoing spinal fusion.

Proceeds will further advance the company's regenerative medicine pipeline of orthobiologic products.

OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries.

The merger will create a company positioned with products and specialized salesforces serving hospital, ambulatory surgical center and office care settings.

The product can be molded to fill defects and supports an environment for bone growth via two formats: putty and strip.

STIMULAN when mixed with antibiotics is the only calcium matrix approved for treating bacterial infection in soft tissue surrounding bone.

Elute received authorization from FDA to use its EP Granules with Tobramycin in a pivotal clinical trial.

FIBERGRAFT BG Putty, FIBERGRAFT BG Putty GPS and FIBERGRAFT BG Morsels are intended for use in the lumbar and anterior cervical spine.

Neo-S is combined with an active principle to form an advanced biomaterial to address the needs of patients with osteoporosis or bone metastasis.

The group purchasing agreement for Synthetic Implantable Products allows Premier members to access pricing and terms for CERAMENT bone void filler.

GreenBone Ortho completed a €10 million (USD ~$11.9 million) Series B investment round, bringing the total raised to €22 million (~$26.3 million) since 2015. GreenBone specializes in bone regeneration using a proprietary 3D scaffold made of natural wood-derived materials....

The grant will fund completion of the company's pre-clinical research, paving the way to initiate a clinical study for this indication.

The app puts user information in the hands of healthcare professionals to support STIMULAN and genex at point of use.

MgNum BVF comprises magnesium, phosphates and a proprietary solution. It has 3x the compressive strength of cancellous bone and adhesive properties.

OssDsign expects to see revenue from Osteo3 ZP bone graft substitute putty during 2H21 following approval processes in U.S. hospitals.

The acquisition underscores Olympus' plan to expand orthopedic minimally invasive surgery products, both organically and through mergers and acquisitions.

Graftys' products are registered in more than 30 countries worldwide, including Europe, the U.S., Canada and South America.

OsteoFlo NanoPutty bone graft features the world's first quadphasic synthetic bone graft particles with nano-surface technology.

The company announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared for spinal fusion.

GreenBone Ortho uses technology that mimics nature to create a long-term solution using rattan, a type of wood, as the base material.

LifeHealthcare will sell STIMULAN and genex calcium matrices for surgical use in musculoskeletal infections, trauma, spine and foot/ankle.

Bioventus received FDA 510(k) clearance to market SIGNAFUSE® Bioactive Bone Graft in a strip format. The strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other synthetic bone graft strips....

STIMULAN is the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue.

Osteo3 ZP Putty combines best-in-class bone repair with intraoperative ease-of-use for spine and trauma bone grafting applications.

BONESUPPORT's bone graft substitutes are based on the patented CERAMENT technology platform. Direct sales commence in July 2020.

This represents the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue.

New preclinical data confirms that local delivery of a bisphosphonate in combination with CERAMENT can regenerate cancellous bone.

BBS-Bioactive Bone Substitutes' patent application protecting ARTEBONE® bone graft substitute has been accepted in the U.S. 

BONESUPPORT will submit a De Novo application for approval of CERAMENT® G in the treatment of osteomyelitis. 

Kuros Biosurgery was granted U.S. patents related to the MagnetOs product line and parathyroid hormones containing matrices for spinal fusion.

Regenerative medicine is an emerging market with solutions to not only heal but also grow tissue and bone. Renovos is addressing the issue of biological molecule diffusion through a synthetic nanoclay gel technology platform called Renovite.

Acumed entered into an agreement to distribute Vivorte's orthobiologic portfolio on an exclusive basis.

Biogennix received FDA 510(k) clearance to market Agilon™ moldable bone graft for use in posterolateral spine procedures when mixed with autograft.

Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate, designed specifically for smaller voids in the foot and ankle.

Bone Solutions announced successful implantation in over 1,000 cases with magnesium-based OsteoCrete® bone void filler.

Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet in the U.S. 

Onkos Surgical is marketing GenVie™ magnesium-based bone void filler through a distribution agreement with Bone Solutions.

GreenBone Ortho received approval under the CE Mark for GreenBone Bone Substitute™.

Biologics4Life completed an exclusive licensing agreement to secure rights to initial technologies for bone tissue regeneration.

Anika Therapeutics is commencing full U.S. commercial launch of TACTOSET surgically-delivered therapy for bone repair procedures.

Advanced Medical Solutions acquired Biomatlante, developer, and manufacturer of orthobiologic products with application in joint reconstruction, spine, trauma, and sports medicine procedures.

ADAM, a 3D bone printing project, plans to complete pre-clinical trials within the month and commence first human trials by the end of 2019.